Patone, Martina
Handunnetthi, Lahiru http://orcid.org/0000-0002-8242-3722
Saatci, Defne
Pan, Jiafeng
Katikireddi, Srinivasa Vittal http://orcid.org/0000-0001-6593-9092
Razvi, Saif http://orcid.org/0000-0003-2307-550X
Hunt, David http://orcid.org/0000-0003-4230-0207
Mei, Xue W. http://orcid.org/0000-0002-6279-4884
Dixon, Sharon
Zaccardi, Francesco
Khunti, Kamlesh
Watkinson, Peter
Coupland, Carol A. C.
Doidge, James http://orcid.org/0000-0002-3674-3100
Harrison, David A.
Ravanan, Rommel http://orcid.org/0000-0003-3324-9024
Sheikh, Aziz http://orcid.org/0000-0001-7022-3056
Robertson, Chris
Hippisley-Cox, Julia http://orcid.org/0000-0002-2479-7283
Article History
Received: 7 July 2021
Accepted: 24 September 2021
First Online: 25 October 2021
Change Date: 29 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-021-01644-8
Competing interests
: A.S. is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group, the Scottish Government’s Standing Committee on Pandemics, and AstraZeneca’s Thrombotic Thrombocytopenic Advisory Group. All roles are unremunerated. D.H. is a member of the Commission on Human Medicine’s Neurology, Pain and Psychiatry Expert Advisory Group. K.K. is a member of the Government Scientific Advisory Group for Emergencies. C.R. is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group, SPI-M, and the MHRA Vaccine Benefit and Risk Committee. J.H.-C. reports grants from the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) (grant number C5255/A18085), through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) and other research councils, during the conduct of the study. J.H.-C. is an unpaid director of QResearch, a not-for-profit organization that is a partnership between the University of Oxford and EMIS Health, who supply the QResearch database used for this work. J.H.-C. is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. J.H.-C. is chair of the NERVTAG risk stratification subgroup and a member of SAGE COVID-19 groups and the NHS group advising on prioritization of use of monoclonal antibodies in COVID-19 infection. All other authors have no competing interests.